从实验室到市场的转化——分子显像剂的开发

From bench to market:translational medicine in the development of molecular imaging agents

在过去的二十年中,转化医学作为一个新兴的领域引起了广泛的关注,从而导致同际上努力推进从实验室到临床应用的转化。以研究神经退行性疾病——帕金森症和阿尔茨海默症的两个脑显像剂TRODAT-1与AV-45的发展转化为例,展示从实验室到FDA注册完成和广泛的临床应用过程的难度以及遭遇的多重障碍。

In the past two decades translational medicine,which encompasses efforts to move discoveries from the laboratory to clinical applications,has received significant attention.We will discuss the recent development of two brain imaging agents for studying neurodegenerative diseases as examples of from bench to clinic.The agents,TRODAT-1 and AV-45(Amyvid),have faced diverse hurdles along the pathway from laboratory to FDA registration and widespread clinical adoption.